These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12207090)

  • 1. Uremia-specific alterations in lipid metabolism.
    Wanner C; Krane V
    Blood Purif; 2002; 20(5):451-3. PubMed ID: 12207090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease.
    Quaschning T; Krane V; Metzger T; Wanner C
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S14-9. PubMed ID: 11576915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dyslipidemia and renal disease: pathogenesis and clinical consequences.
    Wanner C; Quaschning T
    Curr Opin Nephrol Hypertens; 2001 Mar; 10(2):195-201. PubMed ID: 11224694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lipid metabolism abnormalities in Chronic Kidney Disease].
    Bianchi S; Baronti A; Cominotto R; Bigazzi R
    G Ital Nefrol; 2016 Malattie Metaboliche e Rene; 33(S68):. PubMed ID: 27960010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Causes of dysregulation of lipid metabolism in chronic renal failure.
    Vaziri ND
    Semin Dial; 2009; 22(6):644-51. PubMed ID: 20017835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid and lipoprotein metabolism in chronic kidney disease.
    Kaysen GA
    J Ren Nutr; 2009 Jan; 19(1):73-7. PubMed ID: 19121776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of triglyceride-rich lipoproteins-related markers and low-density lipoprotein heterogeneity with cardiovascular risk: effectiveness of polyacrylamide-gel electrophoresis as a method of determining low-density lipoprotein particle size.
    Tani S; Matsumoto M; Nagao K; Hirayama A
    J Cardiol; 2014 Jan; 63(1):60-8. PubMed ID: 24016623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compositional lipoprotein changes and low-density lipoprotein susceptibility to oxidation in chronic renal failure patients with heavy proteinuria.
    Karabina SA; Pappas H; Miltiadous G; Bairaktari E; Christides D; Tselepis A; Elisaf M; Siamopoulos K
    Nephron Clin Pract; 2003; 95(3):c77-83. PubMed ID: 14646367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.
    Chapman MJ; Guérin M; Bruckert E
    Eur Heart J; 1998 Feb; 19 Suppl A():A24-30. PubMed ID: 9519339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
    Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
    Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDL subfractions analysis: a new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia.
    Oravec S; Dostal E; Dukát A; Gavorník P; Kucera M; Gruber K
    Neuro Endocrinol Lett; 2011; 32(4):502-9. PubMed ID: 21876506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
    Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
    Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid disorders and their relevance to outcomes in chronic kidney disease.
    Vaziri ND; Norris K
    Blood Purif; 2011; 31(1-3):189-96. PubMed ID: 21228589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of oral contraceptives on lipid metabolism.
    Krauss RM
    J Reprod Med; 1986 Jun; 31(6 Suppl):549-50. PubMed ID: 3723487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.
    Vaziri ND
    J Ren Nutr; 2010 Sep; 20(5 Suppl):S35-43. PubMed ID: 20797569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.
    Mudd JO; Borlaug BA; Johnston PV; Kral BG; Rouf R; Blumenthal RS; Kwiterovich PO
    J Am Coll Cardiol; 2007 Oct; 50(18):1735-41. PubMed ID: 17964036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein profile in patients who survive a stroke.
    Oravec S; Krivosikova Z; Krivosik M; Gruber K; Gruber M; Dukát A; Gavorník P
    Neuro Endocrinol Lett; 2011; 32(4):496-501. PubMed ID: 21876499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of various lipid-lowering treatments in diabetics.
    Steiner G
    J Cardiovasc Pharmacol; 1990; 16 Suppl 9():S35-9. PubMed ID: 1710744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation.
    Nishizawa Y; Shoji T; Kawagishi T; Morii H
    Kidney Int Suppl; 1997 Nov; 62():S90-2. PubMed ID: 9350691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.